Upload
omar-haqqani
View
90
Download
1
Embed Size (px)
Citation preview
Peripheral Artery Disease:Risk Factor Modification
Dr. Jose L. Raygada, MDMedical Director, Vascular Medicine and Infectious DiseaseVascular Health Clinics
PERIPHERAL ARTERY DISEASE
• What is PAD?• What causes PAD?
• Atherosclerosis• Other: inflammatory & non-inflammatory
• What is atherosclerosis?
J Am Coll Cardiol 2012; 59: 294
EPIDEMIOLOGY OF PAD
• Worldwide prevalence is between 3-12%
• In USA it is estimated that at least 8.5 million persons have PAD
Lancet 2013; 382: 1329
RISK FACTORS FOR PAD
• Smoking• Hypertension• Diabetes• Hyperlipidemia• Homocysteinemia• Metabolic syndrome• Other: age, gender, ethnicity,
low/middle income regions
Circulation 2004; 110: 738
SMOKING CESSATION
• Extremely difficult goal to accomplish - initial success rates are low
• The efficacy of physician advice is < 5%• AHA/ACC recommendations
• All patients should be strongly advised to stop smoking by their physicians
• All patient should be offered counseling and pharmacotherapy• Bupropion• Varenicline• Nicotine replacement therapy
• All patients who are smokers or former smokers should be asked about the status of tobacco use at every visit
J Am Coll Cardiol 2011;58: 2020
SMOKING CESSATION
Bupropion ER (Wellbutrin SR)
• 150 mg PO BID x 7-12 wk; start 150 PO qd x3 days
• Stop smoking after 5-7 days of treatment
SMOKING CESSATION
Varenicline (Chantix)• 1 mg PO bid x11 wk• Start 0.5 mg PO x3 days,
then 0.5 mg PO bid x4 days
• Stop smoking 8-35 days after starting drug if quit date unplanned
• Initial Tx = 12wk (1 start pack + 2 cont. pack); may cont. additional 12 wk if initial tx successful
BLOOD PRESSURE CONTROL
• BP control is an important component of CV risk reduction among patients with PAD - all pts with PAD should undergo BP assessment
• Beta-adrenergic blockers• ACE inhibitors
N Engl J Med 2015:373: 2103
CONTROL OF DIABETES MELLITUS
• Multiple epidemiological studies have established a strong association between DM and PAD
• The relative risk of PAD is up to 4x that of nondiabetic patients
• Therapeutic options include: insulin, sulfonylureas, metformin, the thiazolidinediones (“glitazones”), alpha-glucosidase inhibitors, others
• The standard target HbA1c of less than 7% stands as a recommendation for most patients.
TREATMENT OF HYPERHOMOCYSTEINEMIA
• This is a disorder associated with derangements of the metabolic pathway involved in the metabolism of the essential AA methionine
• Epidemiological studies have established an association between elevated plasma homocysteine levels and CAD and CVD but also PAD
• Vitamin supplementation (folate, B6, B12) is a therapeutic consideration
ANTIPLATELET THERAPY
• The role of antiplatelet therapy in the management of patients with PAD is well established
• The CLIPS study showed that the use of aspirin was associated with a 64% reduction in the relative risk of fatal and nonfatal vascular events and a 58% reduction in fatal and nonfatal vascular events and CLI
• All patients with PAD regardless of concomitant CAD or CVD should receive antiplatelet therapy
• Options: aspirin 81-325 mg PO daily, clopidogrel
• With exception of recent ACS or percutaneous interviention, there is insufficient evidence to support dual therapy
ANTICOAGULANT THERAPY
• Based on the lack of efficacy data for warfarin and the associated risk of bleeding, the routine use of anticoagulation is not recommended
• Anticoagulation therapy may be considered following an episode of acute limb ischemia that had been treated with thrombolytic Rx or may be warranted when there is a comorbid condition associated with increased risk for thromboembolism
STATINS
• Lipid lowering therapy with statins reduces the risk of adverse CV events in patients with atherosclerosis including those with PAD
• Several prospective studies found that statin therapy reduced the risk of new or worsening claudication
• Mechanisms: reduction in plaque size, improvement in vasomotor regulation of blood flow, promotion of angiogenesis, nd increased skeletal muscle metabolic function
MISCELLANEOUS PHARMACOLOGICALAGENTS
• L-arginine• Vitamin E• Ginkgo biloba• Disodium
Ethylenediaminetetracetic Acid (EDTA)